Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10819294 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL2054564 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL4761442 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL14520924 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL14520923 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| Hydrochloric Acid SCHEMBL4326374 | 0.98 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL4713453 | 0.89 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| Hexane SCHEMBL4713252 | 0.88 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL30272567 | 0.86 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL11083508 | 0.85 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904059-A2 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | Wyeth a Corporation of the State of Delaware (US) | 2008-04-02 | — | — | EP | claimed |
| WO-2007013936-A2 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | WYETH (US) | 2007-02-01 | — | — | WO | claimed |
| US-20070021488-A1 | Method for treating nervous system disorders and conditions | WYETH (US) | 2007-01-25 | — | — | US | claimed |
| US-6204284-B1 | ALCOHOL OR COCAINE ABUSE | AMERICAN CYANAMID COMPANY | 2001-03-20 | — | — | US | claimed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | claimed |
| CN-120136849-A | Phenyl-3-azabicyclo [3.1.0] hexane ROR gamma regulator and application thereof | 南京烁慧医药科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120136849-A | Phenyl-3-azabicyclo [3.1.0] hexane ROR gamma regulator and application thereof | 南京烁慧医药科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250115583-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2025-04-10 | — | — | US | disclosed |
| US-12098141-B2 | Bicyclic indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-09-24 | — | — | US | disclosed |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2022-01-20 | — | — | US | disclosed |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2021-04-13 | — | — | US | disclosed |
| US-4839379-A | AROMATASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1989-06-13 | — | — | US | disclosed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
| US-4231935-A | ANXIOLYTICS AND ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4231935-A | ANXIOLYTICS AND ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4196120-A | 1,2-BIS(HYDROCARBYLSULFONYLOXY OR HALO METHYL)CYCLOPROPYLBENZENE, OPTICAL ACITIVITY ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4131611-A | ANXIOLYTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4088652-A | Acylazabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
| US-4088652-A | Acylazabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | SLC6A2 3/4885SLC6A4 8/4885SLC6A3 2/4885 |
| US-20250115583-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR1I2 | SLC6A2 3177/4885SLC6A4 3221/4885SLC6A3 3296/4885 |
| US-12098141-B2 | Bicyclic indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, NR1I2 | SLC6A2 3177/4885SLC6A4 3221/4885SLC6A3 3296/4885 |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, SLC6A2 | SLC6A2 3/4885SLC6A4 8/4885SLC6A3 2/4885 |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR1I2 | SLC6A2 3177/4885SLC6A4 3221/4885SLC6A3 3296/4885 |
| US-20070021488-A1 | Method for treating nervous system disorders and conditions | AVPR1B, AVPR2, AVPR1A | SLC6A2 33/4885SLC6A4 145/4885SLC6A3 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.